Chemotherapy

Classical Massage Mitigates CIPN Due to Adjuvant Chemotherapy for Breast Cancer

Classical Massage Mitigates CIPN Due to Adjuvant Chemotherapy for Breast Cancer

By

Researchers sought to determine if the complementary practice could prevent CIPN in patients receiving adjuvant chemotherapy for breast cancer.

Prophylaxis Improves Postchemotherapy Nausea/Vomiting Frequency, Hospitalizations

Prophylaxis Improves Postchemotherapy Nausea/Vomiting Frequency, Hospitalizations

By

Postchemotherapy hospitalizations and costs are higher for patients receiving highly emetogenic chemotherapy with no prophylaxis treatment.

G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher

G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher

By

A meta-analysis of 14 randomized, controlled trials was conducted to determine if combining G-CSF with intensified chemotherapy improved overall survival.

Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified

Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified

By

Researchers analyzed data from more than 15,000 patients in Southern California with various cancers to identify clinical factors that contribute to the risk of developing chemotherapy-induced febrile neutropenia.

Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis

Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis

By

Results of an open-label phase 2 study demonstrated that a dose-escalation approach can prevent worsening anemia in patients with myelofibrosis undergoing treatment with ruxolitinib.

Nedaplatin Associated With Less Toxicity Than Cisplatin for MPE

Nedaplatin Associated With Less Toxicity Than Cisplatin for MPE

By

In this retrospective study, researchers sought to determine the efficacy of nedaplatin vs cisplatin for the treatment of malignancy-induced malignant pleural effusion.

Chemotherapy Side Effects in Women vs Men: Broader Range, More Severe

Chemotherapy Side Effects in Women vs Men: Broader Range, More Severe

By

An analysis of pooled data from 4 randomized controlled clinical trials revealed that male and female patients experience different chemotherapy side effects and at different severities, according to a poster presented at ESMO 2018 Congress.

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

By

Although brentuximab vedotin offers clinical benefit over bleomycin in first-line treatment of adults with advanced Hodgkin lymphoma, investigators find the drug is not cost-effective.

No Decrease in Pulmonary, Surgical Outcomes With Bleomycin in Good-Risk Germ Cell Cancers

No Decrease in Pulmonary, Surgical Outcomes With Bleomycin in Good-Risk Germ Cell Cancers

By

Researchers investigated whether bleomycin posed concerns regarding pulmonary or operative outcomes following PC-RPLND in men treated with chemotherapy for IGCCCG good-risk germ cell cancers.

Strength and Hope for Women in the Mist of Cancer

Strength and Hope for Women in the Mist of Cancer

By

A review of the most feared effects of breast cancer treatment and resources to recommend to patients coping with these effects.

Delayed Administration Device for Pegfilgratim Safe, Effective in Preventing Grade 4 Neutropenia

Delayed Administration Device for Pegfilgratim Safe, Effective in Preventing Grade 4 Neutropenia

By

In a comparison study, the Onpro® device was found to be a safe and effective alternative to manual injection of pegfilgrastim in patients receiving chemotherapy.

Estimating Quality of Life Based on Cumulative Drug Toxicity in Colorectal Cancer

Estimating Quality of Life Based on Cumulative Drug Toxicity in Colorectal Cancer

By

Results of a study in which more than 100 patients with metastatic colorectal cancer completed EORTC-QLQ-C30 suggests an association between assessment of cumulative drug toxicities and predictions of quality of life for patients undergoing first-line chemotherapy for the disease.

Nedaplatin vs Cisplatin for Malignancy-Induced MPE: Noninferior, Less Toxicity

Nedaplatin vs Cisplatin for Malignancy-Induced MPE: Noninferior, Less Toxicity

By

Researchers sought to determine if nedaplatin could effectively manage malignancy-induced MPE in patients with cancer with less toxicity than cisplatin.

Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma

Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma

By

An updated network meta-analysis found that a triplet regimen consisting of lenalidomide and dexamethasone plus an immunotherapeutic agent had better efficacy in terms of NRR, TTP, PFS, and OS than other regimens.

New Formulations Improve Management of Chemotherapy-Induced Nausea and Vomiting

New Formulations Improve Management of Chemotherapy-Induced Nausea and Vomiting

By

In a recent report, researchers evaluate the efficacy of newer 5HT3-RAs for the prevention of CINV in patients with cancer receiving moderately or highly emetogenic chemotherapy.

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

By

Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

By

Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.

Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma

Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma

By

A phase 2 study was conducted to determine the effectiveness of adding lenalidomide to R-CHOP as a first-line treatment for high-burden follicular lymphoma.

Additional Mammography Between Regular Screenings May Improve Breast Cancer Detection

Additional Mammography Between Regular Screenings May Improve Breast Cancer Detection

By

The MSP in Germany is designed to detect breast cancer during annually scheduled screenings and between the last negative and following screening among survivors.

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

By

Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.

Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score

Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score

By

In a randomization of women with early-stage breast cancer, researchers explored the potential benefits of chemotherapy for women whose Oncotype DX RS was midrange.

Antioxidant Interaction With Cancer Therapy

Antioxidant Interaction With Cancer Therapy

By

What is the concern with antioxidants and chemotherapy or radiation?

Oral Hydration Effectively Reduced Risk of Nephrotoxity After Cisplatin

Oral Hydration Effectively Reduced Risk of Nephrotoxity After Cisplatin

By

A single-center retrospective study determined the safety of IV hydration before and oral hydration after cisplatin therapy to prevent nephrotoxicity in patients with lung cancer vs IV hydration both before and after therapy.

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

By

In an open-label study, researchers sought to determine the optimal amount of bed rest after intrathecal chemotherapy for patients with hematologic cancers.

Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer

Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer

By

Researchers conducted a retrospective analysis to determine the impact of inflammatory responses in patients with ovarian cancer undergoing first-line chemotherapy with or without bevacizumab.

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

By

Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.

Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy

Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy

By

In a randomized study, researchers sought to determine the effect of a nurse-led care program on unscheduled hospital visits and admissions and cost for patients with breast cancer undergoing outpatient chemotherapy.

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

By

Although involved-field radiotherapy (IFRT) has a high level of disease control in patients with follicular lymphoma, relapse frequently occurs; therefore, researchers sought to determine if adding chemotherapy would improve progression-free survival.

Remission Duration Predicts Long-Term Outcomes in Chronic Lymphocytic Leukemia

Remission Duration Predicts Long-Term Outcomes in Chronic Lymphocytic Leukemia

By

A retrospective study sought to evaluate outcomes for patients with CLL who were treated with FCR, a highly effective treatment, and initially had refractory disease, experienced relapse early, or were unable to complete therapy due to toxicity.

Ixazomib, Lenalidomide, Dexamethasone Effective But Increases Toxicity in Multiple Myeloma

Ixazomib, Lenalidomide, Dexamethasone Effective But Increases Toxicity in Multiple Myeloma

By

Three-drug regimen twice a week achieved good response and long-term outcomes in patients with newly diagnosed multiple myeloma; however, regimen has higher toxicity than once weekly dose.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs